NSAID use and risk of leukaemia: a population-based case-control study

Purpose The use of non‐steroidal anti‐inflammatory drugs (NSAIDs) is associated with a reduced risk of developing colorectal and lung cancer. Studies suggesting similar associations in leukaemia have been small and underpowered. We have conducted a large population‐based case‐control study to determ...

Full description

Saved in:
Bibliographic Details
Published inPharmacoepidemiology and drug safety Vol. 18; no. 9; pp. 833 - 836
Main Authors Bhayat, F., Das-Gupta, E., Smith, C., Hubbard, R.
Format Journal Article
LanguageEnglish
Published Chichester, UK John Wiley & Sons, Ltd 01.09.2009
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Purpose The use of non‐steroidal anti‐inflammatory drugs (NSAIDs) is associated with a reduced risk of developing colorectal and lung cancer. Studies suggesting similar associations in leukaemia have been small and underpowered. We have conducted a large population‐based case‐control study to determine whether the use of NSAIDs is associated with a reduced risk of acute and chronic leukaemias, and whether their use has any impact on survival in these patients. Methods We identified all the incident cases of leukaemia in ‘The Health Improvement Network’ (THIN) general practice dataset, along with at least four matched controls per case. We used conditional logistic regression to determine odds ratios for NSAID prescription rates and the risk of developing several leukaemia sub‐types. We then used Cox regression to determine the association between NSAID prescription rate and risk of death in leukaemia. Hazard ratios were adjusted for gender, age at diagnosis, smoking status and Townsend Score. Results The risk of leukaemia overall appears to increase marginally with increased use of NSAIDs prior to diagnosis. This is not seen when individual leukaemia sub‐types are examined, however, except perhaps in CLL where patients who had received 2–5 prescriptions/year are 34% more likely to be diagnosed with CLL than those who had not had any NSAID prescriptions (O.R. 1.34, p = 0.03, 95% C.I. 1.02–1.74). There was no statistically significant association between exposure to NSAIDs prior to leukaemia diagnosis and survival. Conclusion The use of NSAIDs does not reduce the risk of developing leukaemia, nor do they improve survival. Copyright © 2009 John Wiley & Sons, Ltd.
AbstractList Purpose The use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with a reduced risk of developing colorectal and lung cancer. Studies suggesting similar associations in leukaemia have been small and underpowered. We have conducted a large population-based case-control study to determine whether the use of NSAIDs is associated with a reduced risk of acute and chronic leukaemias, and whether their use has any impact on survival in these patients. Methods We identified all the incident cases of leukaemia in 'The Health Improvement Network' (THIN) general practice dataset, along with at least four matched controls per case. We used conditional logistic regression to determine odds ratios for NSAID prescription rates and the risk of developing several leukaemia sub-types. We then used Cox regression to determine the association between NSAID prescription rate and risk of death in leukaemia. Hazard ratios were adjusted for gender, age at diagnosis, smoking status and Townsend Score. Results The risk of leukaemia overall appears to increase marginally with increased use of NSAIDs prior to diagnosis. This is not seen when individual leukaemia sub-types are examined, however, except perhaps in CLL where patients who had received 2-5prescriptions/year are 34% more likely to be diagnosed with CLL than those who had not had any NSAID prescriptions (O.R. 1.34, p=0.03, 95% C.I. 1.02-1.74). There was no statistically significant association between exposure to NSAIDs prior to leukaemia diagnosis and survival. Conclusion The use of NSAIDs does not reduce the risk of developing leukaemia, nor do they improve survival.
The use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with a reduced risk of developing colorectal and lung cancer. Studies suggesting similar associations in leukaemia have been small and underpowered. We have conducted a large population-based case-control study to determine whether the use of NSAIDs is associated with a reduced risk of acute and chronic leukaemias, and whether their use has any impact on survival in these patients. We identified all the incident cases of leukaemia in 'The Health Improvement Network' (THIN) general practice dataset, along with at least four matched controls per case. We used conditional logistic regression to determine odds ratios for NSAID prescription rates and the risk of developing several leukaemia sub-types. We then used Cox regression to determine the association between NSAID prescription rate and risk of death in leukaemia. Hazard ratios were adjusted for gender, age at diagnosis, smoking status and Townsend Score. The risk of leukaemia overall appears to increase marginally with increased use of NSAIDs prior to diagnosis. This is not seen when individual leukaemia sub-types are examined, however, except perhaps in CLL where patients who had received 2-5 prescriptions/year are 34% more likely to be diagnosed with CLL than those who had not had any NSAID prescriptions (O.R. 1.34, p = 0.03, 95% C.I. 1.02-1.74). There was no statistically significant association between exposure to NSAIDs prior to leukaemia diagnosis and survival. The use of NSAIDs does not reduce the risk of developing leukaemia, nor do they improve survival.
Purpose The use of non‐steroidal anti‐inflammatory drugs (NSAIDs) is associated with a reduced risk of developing colorectal and lung cancer. Studies suggesting similar associations in leukaemia have been small and underpowered. We have conducted a large population‐based case‐control study to determine whether the use of NSAIDs is associated with a reduced risk of acute and chronic leukaemias, and whether their use has any impact on survival in these patients. Methods We identified all the incident cases of leukaemia in ‘The Health Improvement Network’ (THIN) general practice dataset, along with at least four matched controls per case. We used conditional logistic regression to determine odds ratios for NSAID prescription rates and the risk of developing several leukaemia sub‐types. We then used Cox regression to determine the association between NSAID prescription rate and risk of death in leukaemia. Hazard ratios were adjusted for gender, age at diagnosis, smoking status and Townsend Score. Results The risk of leukaemia overall appears to increase marginally with increased use of NSAIDs prior to diagnosis. This is not seen when individual leukaemia sub‐types are examined, however, except perhaps in CLL where patients who had received 2–5 prescriptions/year are 34% more likely to be diagnosed with CLL than those who had not had any NSAID prescriptions (O.R. 1.34, p = 0.03, 95% C.I. 1.02–1.74). There was no statistically significant association between exposure to NSAIDs prior to leukaemia diagnosis and survival. Conclusion The use of NSAIDs does not reduce the risk of developing leukaemia, nor do they improve survival. Copyright © 2009 John Wiley & Sons, Ltd.
PURPOSEThe use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with a reduced risk of developing colorectal and lung cancer. Studies suggesting similar associations in leukaemia have been small and underpowered. We have conducted a large population-based case-control study to determine whether the use of NSAIDs is associated with a reduced risk of acute and chronic leukaemias, and whether their use has any impact on survival in these patients.METHODSWe identified all the incident cases of leukaemia in 'The Health Improvement Network' (THIN) general practice dataset, along with at least four matched controls per case. We used conditional logistic regression to determine odds ratios for NSAID prescription rates and the risk of developing several leukaemia sub-types. We then used Cox regression to determine the association between NSAID prescription rate and risk of death in leukaemia. Hazard ratios were adjusted for gender, age at diagnosis, smoking status and Townsend Score.RESULTSThe risk of leukaemia overall appears to increase marginally with increased use of NSAIDs prior to diagnosis. This is not seen when individual leukaemia sub-types are examined, however, except perhaps in CLL where patients who had received 2-5 prescriptions/year are 34% more likely to be diagnosed with CLL than those who had not had any NSAID prescriptions (O.R. 1.34, p = 0.03, 95% C.I. 1.02-1.74). There was no statistically significant association between exposure to NSAIDs prior to leukaemia diagnosis and survival.CONCLUSIONThe use of NSAIDs does not reduce the risk of developing leukaemia, nor do they improve survival.
Abstract Purpose The use of non‐steroidal anti‐inflammatory drugs (NSAIDs) is associated with a reduced risk of developing colorectal and lung cancer. Studies suggesting similar associations in leukaemia have been small and underpowered. We have conducted a large population‐based case‐control study to determine whether the use of NSAIDs is associated with a reduced risk of acute and chronic leukaemias, and whether their use has any impact on survival in these patients. Methods We identified all the incident cases of leukaemia in ‘The Health Improvement Network’ (THIN) general practice dataset, along with at least four matched controls per case. We used conditional logistic regression to determine odds ratios for NSAID prescription rates and the risk of developing several leukaemia sub‐types. We then used Cox regression to determine the association between NSAID prescription rate and risk of death in leukaemia. Hazard ratios were adjusted for gender, age at diagnosis, smoking status and Townsend Score. Results The risk of leukaemia overall appears to increase marginally with increased use of NSAIDs prior to diagnosis. This is not seen when individual leukaemia sub‐types are examined, however, except perhaps in CLL where patients who had received 2–5 prescriptions/year are 34% more likely to be diagnosed with CLL than those who had not had any NSAID prescriptions (O.R. 1.34, p  = 0.03, 95% C.I. 1.02–1.74). There was no statistically significant association between exposure to NSAIDs prior to leukaemia diagnosis and survival. Conclusion The use of NSAIDs does not reduce the risk of developing leukaemia, nor do they improve survival. Copyright © 2009 John Wiley & Sons, Ltd.
Author Bhayat, F.
Das-Gupta, E.
Smith, C.
Hubbard, R.
Author_xml – sequence: 1
  givenname: F.
  surname: Bhayat
  fullname: Bhayat, F.
  email: mcxfb1@exmail.nottingham.ac.uk
  organization: Division of Epidemiology and Public Health, University of Nottingham,UK
– sequence: 2
  givenname: E.
  surname: Das-Gupta
  fullname: Das-Gupta, E.
  organization: Division of Academic Haematology, University of Nottingham, UK
– sequence: 3
  givenname: C.
  surname: Smith
  fullname: Smith, C.
  organization: Division of Epidemiology and Public Health, University of Nottingham,UK
– sequence: 4
  givenname: R.
  surname: Hubbard
  fullname: Hubbard, R.
  organization: Division of Epidemiology and Public Health, University of Nottingham,UK
BackLink https://www.ncbi.nlm.nih.gov/pubmed/19551758$$D View this record in MEDLINE/PubMed
BookMark eNp90E9LwzAYBvAgitMp-AkkJ_HSmTTNkngT558xnQMVwUtI2rdQ1zW1adF9ezMsetJLEsiPh_d99tF25SpA6IiSESUkPqszP6JCqi20R4lSEeVcbG_enEWSj9UA7Xv_Rkj4U8kuGlDFORVc7qHr-ePFdII7D9hUGW4Kv8QuxyV0SwOrwpxjg2tXd6VpC1dF1njIcBrOKHVV27gS-7bL1gdoJzelh8P-HqLn66uny9vo7uFmenlxF6VMkTCXUCJWliojrbQkyQVXFgjkllqZcyGFMFLRsZJgWcYhiXkiCJHWpDZRkLAhOvnOrRv33oFv9arwKZSlqcB1Xo_FmCSCsQBP_4WhJpbweGN_aNo47xvIdd0UK9OsA9KbenWoV2_qDfS4T-3sCrJf2PcZQPQNPooS1n8G6cXksQ_sfeFb-PzxplmGVZjg-mV-o18ni1k8W9xrzr4AZmqS0Q
CitedBy_id crossref_primary_10_1002_pds_1846
crossref_primary_10_1016_j_bbrc_2012_02_092
crossref_primary_10_1016_j_canep_2014_08_003
crossref_primary_10_1158_1055_9965_EPI_11_0411
crossref_primary_10_1002_pds_2191
Cites_doi 10.1592/phco.23.5.686.32205
10.1038/sj.bjc.6604151
10.7326/0003-4819-121-4-199408150-00001
10.1378/chest.127.3.748
10.1136/bmj.302.6779.766
10.1136/bmj.320.7250.1642
10.1186/1471-2407-2-31
10.1016/S0140-6736(07)60747-8
10.1056/NEJMoa021735
10.1002/ijc.20788
ContentType Journal Article
Copyright Copyright © 2009 John Wiley & Sons, Ltd.
Copyright_xml – notice: Copyright © 2009 John Wiley & Sons, Ltd.
DBID BSCLL
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7T2
7U1
7U2
C1K
7X8
DOI 10.1002/pds.1789
DatabaseName Istex
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Health and Safety Science Abstracts (Full archive)
Risk Abstracts
Safety Science and Risk
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Risk Abstracts
Health & Safety Science Abstracts
Safety Science and Risk
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList Risk Abstracts
MEDLINE

MEDLINE - Academic
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1099-1557
EndPage 836
ExternalDocumentID 10_1002_pds_1789
19551758
PDS1789
ark_67375_WNG_ZDPK2KPM_5
Genre article
Journal Article
GroupedDBID ---
.3N
.GA
.Y3
05W
0R~
10A
123
1L6
1OB
1OC
1ZS
31~
33P
3SF
3WU
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABJNI
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFRAH
AFZJQ
AHBTC
AHMBA
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BSCLL
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBD
EBS
EJD
EMOBN
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GNP
GODZA
GWYGA
H.X
HF~
HGLYW
HHZ
HVGLF
HZ~
IX1
J0M
JPC
KBYEO
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LSO
LUTES
LW6
LYRES
M6Q
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RIWAO
RJQFR
ROL
RWI
RX1
RYL
SAMSI
SUPJJ
SV3
TEORI
UB1
V8K
W8V
W99
WBKPD
WHWMO
WIB
WIH
WIJ
WIK
WJL
WOHZO
WQJ
WRC
WUP
WVDHM
WWP
WXI
WXSBR
XG1
XV2
YCJ
ZZTAW
~IA
~WT
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7T2
7U1
7U2
C1K
7X8
ID FETCH-LOGICAL-c3909-179729b19a8b8b04f759be0efb1b8f57877a891698eb3d5e42547008bacb49e43
IEDL.DBID DR2
ISSN 1053-8569
1099-1557
IngestDate Fri Aug 16 05:19:45 EDT 2024
Fri Aug 16 11:55:11 EDT 2024
Fri Aug 23 01:16:53 EDT 2024
Sat Sep 28 07:55:52 EDT 2024
Sat Aug 24 00:53:21 EDT 2024
Wed Oct 30 09:53:27 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 9
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3909-179729b19a8b8b04f759be0efb1b8f57877a891698eb3d5e42547008bacb49e43
Notes No conflict of interest is found in this paper
istex:98AD24F0FDE6002EDD8EE05D1296E905BEBFEDB4
ArticleID:PDS1789
ark:/67375/WNG-ZDPK2KPM-5
Epidemiology.
Public Health.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
PMID 19551758
PQID 1093452473
PQPubID 23462
PageCount 4
ParticipantIDs proquest_miscellaneous_67604733
proquest_miscellaneous_1093452473
crossref_primary_10_1002_pds_1789
pubmed_primary_19551758
wiley_primary_10_1002_pds_1789_PDS1789
istex_primary_ark_67375_WNG_ZDPK2KPM_5
PublicationCentury 2000
PublicationDate September 2009
PublicationDateYYYYMMDD 2009-09-01
PublicationDate_xml – month: 09
  year: 2009
  text: September 2009
PublicationDecade 2000
PublicationPlace Chichester, UK
PublicationPlace_xml – name: Chichester, UK
– name: England
PublicationTitle Pharmacoepidemiology and drug safety
PublicationTitleAlternate Pharmacoepidem. Drug Safe
PublicationYear 2009
Publisher John Wiley & Sons, Ltd
Publisher_xml – name: John Wiley & Sons, Ltd
References Olsen JH, Friis S, Poulsen AH, Fryzek J, Harving H, Tjonneland A, et al. Use of NSAIDs, smoking and lung cancer risk. Br J Canc 2008; 98(1): 232-237.
Moysich KB, Menezes RJ, Ronsani A, Swede H, Reid ME, Cummings KM, et al. Regular aspirin use and lung cancer risk. BMC Cancer 2002; 2: 31.
Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. Br Med J 1991; 302(6779): 766-768.
Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr. Aspirin use and risk of fatal cancer. Canc Res 1993; 53(6): 1322-1327.
Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007; 369(9573): 1603-1613.
Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigomez A, Meier CR, et al. Validity of the general practice research database. Pharmacotherapy 2003; 23(5): 686-689.
Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. New Engl J Med 2003; 348(10): 891-899.
Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. Br Med J 2000; 320(7250): 1642-1646.
Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994; 121(4): 241-246.
Khuder SA, Herial NA, Mutgi AB, Federman DJ. Nonsteroidal antiinflammatory drug use and lung cancer: a metaanalysis. Chest 2005; 127(3): 748-754.
Kasum CM, Blair CK, Folsom AR, Ross JA. Non-steroidal anti-inflammatory drug use and risk of adult leukemia. Canc Epidemiol Biomarkers Prev 2003; 12(6): 534-753.
Pogoda JM, Katz J, McKean-Cowdin R, Nichols PW, Ross RK, Preston-Martin S. Prescription drug use and risk of acute myeloid leukemia by French-American-British subtype: results from a Los Angeles County case-control study. Int J Canc 2005; 114(4): 634-638.
1994; 121
2007; 369
2003; 348
2005; 114
1993; 53
2005; 127
2002; 2
2007
2008; 98
2000; 320
1991; 302
2003; 12
1999
2003; 23
Thun MJ (e_1_2_1_4_2) 1993; 53
e_1_2_1_6_2
e_1_2_1_7_2
e_1_2_1_5_2
e_1_2_1_2_2
e_1_2_1_3_2
e_1_2_1_12_2
e_1_2_1_10_2
Kasum CM (e_1_2_1_11_2) 2003; 12
e_1_2_1_15_2
e_1_2_1_13_2
e_1_2_1_14_2
e_1_2_1_8_2
e_1_2_1_9_2
References_xml – volume: 348
  start-page: 891
  issue: 10
  year: 2003
  end-page: 899
  article-title: A randomized trial of aspirin to prevent colorectal adenomas
  publication-title: New Engl J Med
– volume: 302
  start-page: 766
  issue: 6779
  year: 1991
  end-page: 768
  article-title: Validation of information recorded on general practitioner based computerised data resource in the United Kingdom
  publication-title: Br Med J
– volume: 127
  start-page: 748
  issue: 3
  year: 2005
  end-page: 754
  article-title: Nonsteroidal antiinflammatory drug use and lung cancer: a metaanalysis
  publication-title: Chest
– volume: 114
  start-page: 634
  issue: 4
  year: 2005
  end-page: 638
  article-title: Prescription drug use and risk of acute myeloid leukemia by French‐American‐British subtype: results from a Los Angeles County case‐control study
  publication-title: Int J Canc
– volume: 23
  start-page: 686
  issue: 5
  year: 2003
  end-page: 689
  article-title: Validity of the general practice research database
  publication-title: Pharmacotherapy
– volume: 369
  start-page: 1603
  issue: 9573
  year: 2007
  end-page: 1613
  article-title: Effect of aspirin on long‐term risk of colorectal cancer: consistent evidence from randomised and observational studies
  publication-title: Lancet
– year: 2007
– volume: 121
  start-page: 241
  issue: 4
  year: 1994
  end-page: 246
  article-title: Aspirin use and the risk for colorectal cancer and adenoma in male health professionals
  publication-title: Ann Intern Med
– volume: 320
  start-page: 1642
  issue: 7250
  year: 2000
  end-page: 1646
  article-title: Effect of anti‐inflammatory drugs on overall risk of common cancer: case‐control study in general practice research database
  publication-title: Br Med J
– volume: 98
  start-page: 232
  issue: 1
  year: 2008
  end-page: 237
  article-title: Use of NSAIDs, smoking and lung cancer risk
  publication-title: Br J Canc
– volume: 12
  start-page: 534
  issue: 6
  year: 2003
  end-page: 753
  article-title: Non‐steroidal anti‐inflammatory drug use and risk of adult leukemia
  publication-title: Canc Epidemiol Biomarkers Prev
– volume: 2
  start-page: 31
  year: 2002
  article-title: Regular aspirin use and lung cancer risk
  publication-title: BMC Cancer
– volume: 53
  start-page: 1322
  issue: 6
  year: 1993
  end-page: 1327
  article-title: Aspirin use and risk of fatal cancer
  publication-title: Canc Res
– year: 1999
– ident: e_1_2_1_15_2
  doi: 10.1592/phco.23.5.686.32205
– ident: e_1_2_1_5_2
  doi: 10.1038/sj.bjc.6604151
– ident: e_1_2_1_3_2
  doi: 10.7326/0003-4819-121-4-199408150-00001
– volume: 53
  start-page: 1322
  issue: 6
  year: 1993
  ident: e_1_2_1_4_2
  article-title: Aspirin use and risk of fatal cancer
  publication-title: Canc Res
  contributor:
    fullname: Thun MJ
– ident: e_1_2_1_6_2
  doi: 10.1378/chest.127.3.748
– ident: e_1_2_1_13_2
– ident: e_1_2_1_14_2
  doi: 10.1136/bmj.302.6779.766
– ident: e_1_2_1_2_2
  doi: 10.1136/bmj.320.7250.1642
– ident: e_1_2_1_7_2
  doi: 10.1186/1471-2407-2-31
– ident: e_1_2_1_8_2
  doi: 10.1016/S0140-6736(07)60747-8
– ident: e_1_2_1_9_2
  doi: 10.1056/NEJMoa021735
– ident: e_1_2_1_12_2
– ident: e_1_2_1_10_2
  doi: 10.1002/ijc.20788
– volume: 12
  start-page: 534
  issue: 6
  year: 2003
  ident: e_1_2_1_11_2
  article-title: Non‐steroidal anti‐inflammatory drug use and risk of adult leukemia
  publication-title: Canc Epidemiol Biomarkers Prev
  contributor:
    fullname: Kasum CM
SSID ssj0009994
Score 1.9382392
Snippet Purpose The use of non‐steroidal anti‐inflammatory drugs (NSAIDs) is associated with a reduced risk of developing colorectal and lung cancer. Studies...
The use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with a reduced risk of developing colorectal and lung cancer. Studies suggesting...
Abstract Purpose The use of non‐steroidal anti‐inflammatory drugs (NSAIDs) is associated with a reduced risk of developing colorectal and lung cancer. Studies...
Purpose The use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with a reduced risk of developing colorectal and lung cancer. Studies...
PURPOSEThe use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with a reduced risk of developing colorectal and lung cancer. Studies suggesting...
SourceID proquest
crossref
pubmed
wiley
istex
SourceType Aggregation Database
Index Database
Publisher
StartPage 833
SubjectTerms Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
Antiinflammatory agents
Cancer
Case-Control Studies
chemo-prevention
epidemiology
Gender
Humans
leukaemia
Leukemia
Leukemia - epidemiology
Logistic Models
Lung cancer
Mortality
non-steroidal anti-inflammatory drugs
Risk Factors
Risk reduction
Smoking
Survival
Title NSAID use and risk of leukaemia: a population-based case-control study
URI https://api.istex.fr/ark:/67375/WNG-ZDPK2KPM-5/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fpds.1789
https://www.ncbi.nlm.nih.gov/pubmed/19551758
https://search.proquest.com/docview/1093452473
https://search.proquest.com/docview/67604733
Volume 18
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwELYqeukF-uCxhbZGQnsiSzZxYrs31C3lIVYRD4HgYNmxI6FtsyuykUpP_Qn9jf0lnUk2G1GBhLgkijSJHM94_Nkz85mQLWmNH1iLIX_nPKZF7GnDOe42cR6Dd-RVUdjxMN4_Z4eX0eUsqxJrYWp-iPmGG46Myl_jANem2GlJQye26PW5wNq9fsgxm2tw0jJHAe6pAspgY56IYtnwzvrBTvPivZnoJXbqz4dg5n3UWk07e0vkumlwnW0y6pVT00t__cfl-Lw_ek0WZ2iU7tbm84a8cPlb0k1qOuu7bXrWVmcV27RLk5bo-u4dORye7h4MaFk4qnNLMUudjjP63ZUj7X7c6M9U08n8gLC_v__glGlpCld4mCXJ04rgdpmc7309-7Lvzc5m8NJQ4gkKXAIsN32phRHGZxmPpHG-y0zfiAzdANcCoKcUsFq3kQPXwDjgDaNTw6Rj4QpZyMe5WyPUMuvSjMGbKWM2SLXQSJoDUMdEBhYAHbLZ6ElNagoOVZMtBwq6TGGXdUi3UuBcQN-OMGWNR-pi-E1dDZKj4Cg5VhF8rNGwgoGE0RGdu3FZYCg-ZFHAeNghnx6RiXnsgwBIrNbG0TZIAvSEtRc0pFLxoy1VyeAU7--fKrhOXtURLMxr2yAL09vSfQAgNDUfK5P_B0d-BWE
link.rule.ids 315,783,787,1378,27936,27937,46306,46730
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fa9swEBdd-7C9tPvbpvtTDUae6tSxZUvansqyLm2aYNaUlTEQkiVDyeaEJoZ1T_sI-4z7JLuz45iOFcZebAxnc5Z0p590p98R8kpa4wfWYsjfOY9pEXvacI67TZzH4B15eShsOIr75-zkIrpYI2_qszAVP8Rqww0to_TXaOC4IX3QsIbO7LzT5ULeIRtg7SHWbeh9aLijAPmUIWUYZZ6IYlkzz_rBQf3mjbloA5v129-A5k3cWk48R1vkc61ylW8y6RQL00m__8Hm-J__dJ9sLgEpPaxG0AOy5vKHpJ1UjNbX-3TcHNCa79M2TRqu6-tH5GR0dnjco8XcUZ1bionqdJrRL66YaPf1Ur-mms5WNcJ-_fiJs6alKVzhYZknT0uO28fk_Ojd-G3fW5Zn8NJQYhEFLgGZm67Uwgjjs4xH0jjfZaZrRIaegGsB6FMKWLDbyIF3YBwgh9GpYdKx8AlZz6e52yHUMuvSjMGbKWM2SLXQyJsDaMdEBtYALfKy7ig1q1g4VMW3HChoMoVN1iLtsgdXAvpqgllrPFIfR-_Vp14yCAbJUEXwsbqLFdgSBkh07qbFHKPxIYsCxsMW2btFJuaxDwIgsV2NjkYhCegTll-gSNnHt2qqkt4Z3nf_VXCP3O2Ph6fq9Hg0eEruVQEtTHN7RtYXV4V7DrhoYV6U4_83fq8JeQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED_BJiFe-P4oXzMS6tPSpakT27xNlLKtrIrYJqbxYNmxI6FCWq2NxHjiT-Bv5C_hLmkaDTEJ8ZIo0iW6-M7nn33nnwFeKWfDyDlK-XsfcCOTwFghaLVJiASjo6g2hR1Okr0TfnAan66qKmkvTM0PsV5wo55RxWvq4HOX77SkoXO36PWFVNdhkycIfAkQfWipoxD4VBlldLJAxolqiGfDaKd589JQtEmt-u1vOPMybK3GndFt-NRoXJebTHvl0vay73-QOf7fL92BWys4ynZr_7kL13xxD7ppzWd9sc2O2-1Zi23WZWnLdH1xHw4mR7v7Q1YuPDOFY1SmzmY5--LLqfFfP5vXzLD5-oSwXz9-0pjpWIZXfFhVybOK4fYBnIzeHr_ZC1aHMwTZQNERCkIhLrd9ZaSVNuS5iJX1oc9t38qc4oAwErGnkjhdd7HH2MAFAg5rMsuV54OHsFHMCv8YmOPOZznHNzPOXZQZaYg1B7GOjS3OADrwsrGTntccHLpmW440NpmmJutAtzLgWsCcT6lmTcT64-SdPhum42icHuoYP9ZYWGNPovSIKfysXFAufsDjiItBB7aukElEEqIASjyqnaNVSCH2xMkXKlKZ-EpNdTo8ovuTfxXcghvpcKTf70_GT-Fmnc2iGrdnsLE8L_1zBEVL-6Ly_t9mDwgo
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=NSAID+use+and+risk+of+leukaemia%3A+a+population-based+case-control+study&rft.jtitle=Pharmacoepidemiology+and+drug+safety&rft.au=Bhayat%2C+F.&rft.au=Das-Gupta%2C+E.&rft.au=Smith%2C+C.&rft.au=Hubbard%2C+R.&rft.date=2009-09-01&rft.pub=John+Wiley+%26+Sons%2C+Ltd&rft.issn=1053-8569&rft.eissn=1099-1557&rft.volume=18&rft.issue=9&rft.spage=833&rft.epage=836&rft_id=info:doi/10.1002%2Fpds.1789&rft.externalDBID=n%2Fa&rft.externalDocID=ark_67375_WNG_ZDPK2KPM_5
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1053-8569&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1053-8569&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1053-8569&client=summon